NCT03041181 2022-07-11
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Hoosier Cancer Research Network
Phase 2 Terminated
Hoosier Cancer Research Network
Novartis
Radiation Therapy Oncology Group
SWOG Cancer Research Network
National Cancer Institute (NCI)
SWOG Cancer Research Network